Thomas C Wilson
Overview
Explore the profile of Thomas C Wilson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
454
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Donnelly D, Preshlock S, Kaur T, Tran T, Wilson T, Mhanna K, et al.
Front Nucl Med
. 2024 Oct;
1:820235.
PMID: 39355640
Positron emission tomography (PET) is an important non-invasive tool to help guide the drug discovery and development process. Positron-emitting-radiolabeled drug candidates represent an important tool for drug hunters to gain...
2.
Joshi S, Wilson T, Li Z, Preshlock S, Gomez-Vallejo V, Gouverneur V, et al.
Molecules
. 2024 Jan;
29(2).
PMID: 38257401
The small-molecule iododiflunisal (IDIF) is a transthyretin (TTR) tetramer stabilizer and acts as a chaperone of the TTR-Amyloid beta interaction. Oral administration of IDIF improves Alzheimer's Disease (AD)-like pathology in...
3.
Chan C, Chen Z, Guibbal F, Dias G, Destro G, ONeill E, et al.
J Nucl Med
. 2023 Sep;
64(12):1965-1971.
PMID: 37770109
Poly(adenosine diphosphate ribose) polymerase (PARP) has emerged as an effective therapeutic strategy against cancer that targets the DNA damage repair enzyme. PARP-targeting compounds radiolabeled with an Auger electron-emitting radionuclide can...
4.
5.
Chan C, Hopkins S, Guibbal F, Pacelli A, Torres J, Mosley M, et al.
EJNMMI Res
. 2022 Oct;
12(1):67.
PMID: 36210377
Purpose: Radiopharmaceuticals targeting poly(ADP-ribose) polymerase (PARP) have emerged as promising agents for cancer diagnosis and therapy. PARP enzymes are expressed in both cancerous and normal tissue. Hence, the injected mass,...
6.
Pirovano G, Wilson T, Reiner T
Nucl Med Biol
. 2021 Apr;
96-97:50-53.
PMID: 33831745
First reported by Lise Meitner in 1922 and independently by Pierre Auger in 1923, the Auger effect has been explored as a potential source for targeted radiotherapy. The Auger effect...
7.
Fuchs A, Wilson T, Kitrinos C, Kunaparaju A, Bell R
Evol Anthropol
. 2021 Jan;
30(2):102-104.
PMID: 33459449
No abstract available.
8.
Gonzales J, Hernandez-Gil J, Wilson T, Adilbay D, Cornejo M, Demetrio de Souza Franca P, et al.
Mol Pharm
. 2021 Jan;
18(3):940-951.
PMID: 33404254
Almost 17 million Americans have a history of cancer, a number expected to reach over 22 million by 2030. Cancer patients often undergo chemotherapy in the form of antineoplastic agents...
9.
Turnock S, Turton D, Martins C, Chesler L, Wilson T, Gouverneur V, et al.
Sci Rep
. 2020 Dec;
10(1):20918.
PMID: 33262374
Targeted radiotherapy with I-mIBG, a substrate of the human norepinephrine transporter (NET-1), shows promising responses in heavily pre-treated neuroblastoma (NB) patients. Combinatorial approaches that enhance I-mIBG tumour uptake are of...
10.
Richter A, Wilson T
Geneva Risk Insur Rev
. 2020 Sep;
45(2):171-199.
PMID: 32982612
This paper analyzes the insurability of pandemic risk and outlines how underwriting policies and scenario analysis are used to build resilience upfront and plan contingency actions for crisis scenarios. It...